Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia

Publication date

2019-08-01

Authors

Favié, LMA
Groenendaal, FlorisORCID 0000-0002-9284-1637ISNI 0000000393055993
van den Broek, Marcel P HISNI 0000000393141939
Rademaker, KarinISNI 0000000389627127
De Haan, Timo R.
Van Straaten, Henrica L.M.
Dijk, Peter H.
Van Heijst, Arno
Simons, Sinno H.P.
Dijkman, Koen P.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

Abstract

Background: Phenobarbital and midazolam are commonly used drugs in (near-)term neonates treated with therapeutic hypothermia for hypoxic-ischaemic encephalopathy, for sedation, and/or as anti-epileptic drug. Phenobarbital is an inducer of cytochrome P450 (CYP) 3A, while midazolam is a CYP3A substrate. Therefore, co-treatment with phenobarbital might impact midazolam clearance. Objectives: To assess pharmacokinetics and clinical anti-epileptic effectiveness of phenobarbital and midazolam in asphyxiated neonates and to develop dosing guidelines. Methods: Data were collected in the prospective multicentre PharmaCool study. In the present study, neonates treated with therapeutic hypothermia and receiving midazolam and/or phenobarbital were included. Plasma concentrations of phenobarbital and midazolam including its metabolites were determined in blood samples drawn on days 2-5 after birth. Pharmacokinetic analyses were performed using non-linear mixed effects modelling; clinical effectiveness was defined as no use of additional anti-epileptic drugs. Results: Data were available from 113 (phenobarbital) and 118 (midazolam) neonates; 68 were treated with both medications. Only clearance of 1-hydroxy midazolam was influenced by hypothermia. Phenobarbital co-administration increased midazolam clearance by a factor 2.3 (95% CI 1.9-2.9, p < 0.05). Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam. Conclusions: Therapeutic hypothermia does not influence clearance of phenobarbital or midazolam in (near-)term neonates with hypoxic-ischaemic encephalopathy. A phenobarbital dose of 30 mg/kg is advised to reach therapeutic concentrations. Phenobarbital co-administration significantly increased midazolam clearance. Should phenobarbital be substituted by non-CYP3A inducers as first-line anticonvulsant, a 50% lower midazolam maintenance dose might be appropriate to avoid excessive exposure during the first days after birth.

Keywords

Hypoxic-ischaemic encephalopathy, Midazolam, Neonates, Pharmacokinetics, Phenobarbital, Pediatrics, Perinatology, and Child Health, Developmental Biology, Journal Article

Citation

Favié, L M A, Groenendaal, F, Van Den Broek, M P H, Rademaker, C M A, De Haan, T R, Van Straaten, H L M, Dijk, P H, Van Heijst, A, Simons, S H P, Dijkman, K P, Rijken, M, Zonnenberg, I A, Cools, F, Zecic, A, Van Der Lee, J H, Nuytemans, D H G M, Van Bel, F, Egberts, T C G & Huitema, A D R 2019, 'Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia', Neonatology, vol. 116, no. 2, pp. 154-162. https://doi.org/10.1159/000499330